S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83

Compare Stocks

Date Range: 

 AIkido PharmaBioqualInhibitor TherapeuticsHedgePath PharmaceuticalsiSpecimen
SymbolNASDAQ:AIKIOTCMKTS:BIOQOTCMKTS:INTIOTCMKTS:HPPINASDAQ:ISPC
Price Information
Current Price$0.70$100.00$0.14$0.14$12.23
50-Day Moving Average$0.76$91.39$0.16$0.16$7.78
52-Week Low$0.55$70.00$0.02$0.04$4.75
52-Week High$2.55$100.00$0.35$0.32$28.98
MarketRank™
Overall Score1.71.80.00.80.3
Analysis Score3.50.00.00.00.0
Community Score4.54.50.04.00.0
Dividend Score0.01.70.00.00.0
Ownership Score0.01.70.00.01.7
Earnings & Valuation Score0.61.30.00.00.0
Analyst Ratings
Consensus RecommendationBuyN/AN/AN/AN/A
Consensus Price Target$2.00N/AN/AN/AN/A
% Upside from Price Target187.73% upsideN/AN/AN/AN/A
Trade Information
Market Cap$62.34 million$89.60 million$50.88 million$50.01 million$85.57 million
Beta1.42-0.41-0.29-1.16N/A
Average Volume7,417,92536524,75019,2832,879,665
Sales & Book Value
Annual Revenue$10 thousand$57.68 millionN/AN/A$8.18 million
Price / Sales6,233.731.55N/AN/A10.46
CashflowN/A$4.14 per shareN/AN/AN/A
Price / CashN/A24.15N/AN/AN/A
Book Value$1.15 per shareN/A($0.02) per share($0.01) per share$1.73 per share
Price / Book0.60N/AN/A7.07
Profitability
Net Income$-12.34 million$6.33 million$-1.06 million$-4.55 million$-4.65 million
EPS($0.04)$6.64N/AN/AN/A
Trailing P/E RatioN/A15.060.000.000.00
Forward P/E RatioN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A10.19%N/AN/AN/A
Return on Equity (ROE)-5.92%N/AN/AN/AN/A
Return on Assets (ROA)-5.85%N/A-257.39%-246.03%N/A
Dividend
Annual PayoutN/A$1.25N/AN/AN/A
Dividend YieldN/A1.25%N/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/A18.83%N/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/A0.28
Current Ratio54.07N/A0.156.767.08
Quick Ratio54.07N/A0.156.767.08
Ownership Information
Institutional Ownership Percentage10.34%N/AN/AN/A16.22%
Insider Ownership Percentage0.62%39.24%4.60%4.80%N/A
Miscellaneous
Employees51142237
Shares Outstanding89.68 million896,000376.86 million370.45 million7.00 million
Next Earnings Date3/24/2022 (Estimated)1/20/2022 (Estimated)N/AN/A2/3/2022 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
iSpecimen Inc. (NASDAQ: ISPC)’S Stock Adds 0.48%, But It May Be Worth Investing IniSpecimen Inc. (NASDAQ: ISPC)’S Stock Adds 0.48%, But It May Be Worth Investing In
stocksregister.com - December 7 at 1:19 PM
AIkido Pharma (NASDAQ:AIKI) and iSpecimen (NASDAQ:ISPC) Critical AnalysisAIkido Pharma (NASDAQ:AIKI) and iSpecimen (NASDAQ:ISPC) Critical Analysis
americanbankingnews.com - December 7 at 5:18 AM
iSpecimen Inc.s Lock-Up Period To Expire  on December 14th (NASDAQ:ISPC)iSpecimen Inc.'s Lock-Up Period To Expire on December 14th (NASDAQ:ISPC)
americanbankingnews.com - December 7 at 1:24 AM
iSpecimen Inc. (ISPC) Stock: Looks Like A Good InvestmentiSpecimen Inc. (ISPC) Stock: Looks Like A Good Investment
stocksregister.com - December 3 at 3:33 PM
Head to Head Survey: iSpecimen (NASDAQ:ISPC) & Absci (NASDAQ:ABSI)Head to Head Survey: iSpecimen (NASDAQ:ISPC) & Absci (NASDAQ:ABSI)
americanbankingnews.com - December 3 at 5:10 AM
iSpecimen Expands Supplier Network of Human Biospecimens to Help Advance Research in Neurological DisordersiSpecimen Expands Supplier Network of Human Biospecimens to Help Advance Research in Neurological Disorders
finance.yahoo.com - December 2 at 7:45 AM
iSpecimen Inc. Announces Closing of Approximately $21 Million Private PlacementiSpecimen Inc. Announces Closing of Approximately $21 Million Private Placement
prnewswire.com - December 1 at 10:47 PM
Market cap of iSpecimen Inc. [ISPC] reaches 126.52M – now what?Market cap of iSpecimen Inc. [ISPC] reaches 126.52M – now what?
dbtnews.com - December 1 at 8:25 PM
ISpecimen To Privately Place $21 Mln Of SharesISpecimen To Privately Place $21 Mln Of Shares
nasdaq.com - November 29 at 6:30 AM
iSpecimen Inc. Announces $21 Million Private PlacementiSpecimen Inc. Announces $21 Million Private Placement
finance.yahoo.com - November 29 at 6:30 AM
With stock up 256%, Insiders of iSpecimen Inc. (NASDAQ:ISPC) must be wishing they had bought more last yearWith stock up 256%, Insiders of iSpecimen Inc. (NASDAQ:ISPC) must be wishing they had bought more last year
nasdaq.com - November 27 at 11:33 AM
Is iSpecimen Inc. (NASDAQ:ISPC) Popular Amongst Insiders?Is iSpecimen Inc. (NASDAQ:ISPC) Popular Amongst Insiders?
finance.yahoo.com - November 27 at 11:33 AM
Here is why iSpecimen is up 50% todayHere is why iSpecimen is up 50% today
invezz.com - November 23 at 5:59 PM
Tag: NASDAQ:ISPCTag: NASDAQ:ISPC
stocksregister.com - November 23 at 12:59 PM
Financial Contrast: iSpecimen (NASDAQ:ISPC) and AIkido Pharma (NASDAQ:AIKI)Financial Contrast: iSpecimen (NASDAQ:ISPC) and AIkido Pharma (NASDAQ:AIKI)
americanbankingnews.com - November 23 at 9:16 AM
Pre-market Movers: PTPI, ISPC, QLGN, AADI, BTB…Pre-market Movers: PTPI, ISPC, QLGN, AADI, BTB…
markets.businessinsider.com - November 23 at 7:40 AM
iSpecimen Inc. [ISPC] moved up 80.49: Why It’s ImportantiSpecimen Inc. [ISPC] moved up 80.49: Why It’s Important
dbtnews.com - November 23 at 7:40 AM
Christopher IanelliChristopher Ianelli
benzinga.com - November 22 at 3:45 PM
Mid-Day Market Update: Gold Down 2%; iSpecimen Shares Spike HigherMid-Day Market Update: Gold Down 2%; iSpecimen Shares Spike Higher
markets.businessinsider.com - November 22 at 3:45 PM
iSpecimen Shares Soar After Being Picked for Critical Covid-19 ResearchiSpecimen Shares Soar After Being Picked for Critical Covid-19 Research
finance.yahoo.com - November 22 at 3:45 PM
Why ISpecimens Stock Is Soaring TodayWhy ISpecimen's Stock Is Soaring Today
benzinga.com - November 22 at 3:45 PM
iSpecimen Selected by U.S. Government and Private Researchers to Supply Critical Human Biospecimens for Advanced Phase of COVID-19 ResearchiSpecimen Selected by U.S. Government and Private Researchers to Supply Critical Human Biospecimens for Advanced Phase of COVID-19 Research
finance.yahoo.com - November 22 at 9:51 AM
iSpecimen Inc. (NASDAQ:ISPC) Short Interest UpdateiSpecimen Inc. (NASDAQ:ISPC) Short Interest Update
americanbankingnews.com - November 19 at 6:42 AM
Tracy Curley Acquires 8,000 Shares of iSpecimen Inc. (NASDAQ:ISPC) StockTracy Curley Acquires 8,000 Shares of iSpecimen Inc. (NASDAQ:ISPC) Stock
americanbankingnews.com - November 17 at 11:28 PM
iSpecimen Reports Third Quarter 2021 Financial ResultsiSpecimen Reports Third Quarter 2021 Financial Results
finance.yahoo.com - November 4 at 7:21 AM
DateCompanyBrokerageAction
10/11/2021AIkido PharmaHC Wainwright
Initiated Coverage
(Data available from 12/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.